Literature DB >> 3588110

Pertussis in Sweden after the cessation of general immunization in 1979.

V Romanus, R Jonsell, S O Bergquist.   

Abstract

Immunization against pertussis was introduced in Sweden in the 1950s and discontinued in 1979. This was followed by a low endemic level of pertussis for 3 years. Thereafter the incidence gradually increased and there were two outbreaks in 1983 and in 1985. In the period 1980 to 1985 pertussis was confirmed by culture or serology in 36,729 patients of which 11% were younger than 12 months of age and 69% were ages 1 to 6 years. An estimate of the total frequency of pertussis in preschool children was made from reports from a sample of the child health centers. The annual incidence rate per 100,000 population ages 0 to 6 years increased from the 700 cases in 1981 to 3200 in 1985. The ratio of total cases to those reported from the laboratories was 3:1 in 1981 and 2:1 in 1985. The cumulative incidence rate by the average age of 4 years was estimated at 16% of the unimmunized cohort born in 1980 compared with 5% of the immunized cohort born in 1978. The seriousness of pertussis was evaluated by studying the 2282 pertussis patients hospitalized from 1981 to the end of 1983. Forty-eight percent were infants younger than 12 months of age. Neurologic complications were noted in 4% and pneumonia in 14% of the hospitalized patients. Eleven children received assisted ventilation. Fatal outcomes were reported in 3 children (0.1%), 2 of whom had severe congenital disabilities.

Entities:  

Mesh:

Year:  1987        PMID: 3588110     DOI: 10.1097/00006454-198704000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  35 in total

1.  Role of endotoxin in alterations of hepatic drug metabolism by diphtheria and tetanus toxoids and pertussis vaccine adsorbed.

Authors:  S Ansher; W Thompson; P Snoy; W Habig
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 2.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

3.  Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Authors:  Hans O Hallander; Abdolreza Advani; Declan Donnelly; Lennart Gustafsson; Rose-Marie Carlsson
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis.

Authors:  C A Guzmán; R M Brownlie; J Kadurugamuwa; M J Walker; K N Timmis
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

Review 5.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

6.  Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.

Authors:  G Tormans; E Van Doorslaer; P van Damme; R Clara; H J Schmitt
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 7.  Pertussis: the disease and new diagnostic methods.

Authors:  R L Friedman
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

8.  Vaccines modulate IDDM.

Authors:  J B Classen; D C Classen
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 9.  The past, present, and future of pertussis. The role of adults in epidemiology and future control.

Authors:  J D Cherry; L J Baraff; E Hewlett
Journal:  West J Med       Date:  1989-03

Review 10.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.